2019 CYIR Finalized

34 GENERAL CRITICAL CARE GENERAL CRITICAL CARE Rebecca M. Baron, MD Brigham and Women’s Hospital Pulmonary and Critical Care Medicine Boston, MA PHARMACOLOGIC MANAGEMENT OF DELIRIUM IN CRITICAL ILLNESS Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, Douglas IS, Malhotra A, Owens RL, Feinstein DJ, Khan B, Pisani MA, Hyzy RC, Schmidt GA, Schweickert WD, Hite RD, Bowton DL, Masica AL, Thompson JL, Chandrasekhar R, Pun BT, Strength C, Boehm LM, Jackson JC, Pandharipande PP, Brummel NE, Hughes CG, Patel MB, Stollings JL, Bernard GR, Dittus RS, Ely EW for the MIND-USA Investigators. H aloperidol and ziprasidone for the treatment of delirium in critical illness. N Engl J Med 2018; 379:2506-2516 Summary There is a high incidence of delirium in critically ill patients (as high as 30%) that is associated with enhanced morbid- ity and mortality. Prior literature has demonstrated con- flicting findings as to whether antipsychotic medications prevent or treat delirium in ICU patients. Thus, it is unclear whether antipsychotic agents should play a role in preven- tion or treatment of ICU delirium. The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND- USA) trial examined the effect of haloperidol (typical anti- psychotic, n=192) vs. ziprasidone (atypical antipsychotic, n=190) vs. placebo, n=184) in critically ill subjects with acute respiratory failure or shock with confirmed delirium in a multicenter, double-blind, randomized trial across 16 U.S. hospitals. There was no difference between treat- ment groups for the primary outcome of days alive without delirium or coma, nor in secondary outcomes (including survival and length of ICU and hospital stay or decrease in sedation requirements), nor in safety end points (including frequency of extrapyramidal symptoms and corrected QT prolongation). Comments 1. This MIND-USA study demonstrated no benefit of typical or atypical antipsychotic medication in reducing the duration of delirium (primary outcome) nor in decreasing sedation require- ments (secondary outcome). 2. Of note, the REDUCE trial, also published this year, demon- strated no mortality benefit of prophylactic haloperidol in criti- cally ill patients at risk for delirium. 3. There was prior uncertainty as to the role of typical vs. atypical antipsychotic medications in management of ICU delirium, and the MIND-USA study was the first large trial to compare these classes of medications vs. placebo (although it is noted that use of the antipsychotic quetiapine is likely more common than ziprasidone that was used in this study). 4. It remains uncertain whether there might be other agents that might prevent delirium that are currently under investigation. 5. The MIND-USA study had a high proportion of patients with hypoactive delirium (89%), so it remains unclear whether patients with hyperactive delirium might benefit in terms of control of agitation with antipsychotic medications. ADJUNCTIVE HYDROCORTISONE FOR SEPTIC SHOCK Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E; CRICS- TRIGGERSEP Network. Hydrocortisone plus fludrocor- tisone for adults with septic shock. N Engl J Med 2018; 378:809-818. (APROCCHSS) Summary While high dose steroids were shown to be harmful in septic shock, numerous studies examining low-dose ste- roids (e.g. hydrocortisone 200 mg/day) in septic shock demonstrated conflicting results. Within the last year, two large randomized, blinded, multicenter controlled studies of low-dose steroids in septic shock also yielded conflict- ing results, but given differences in the trials, perhaps additional information can be gleaned. The Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial is reviewed by another speaker and randomized 3,800 patients with vasopressor-dependent septic shock and mechanical ventilation to a 7-day hydro- cortisone infusion (200 mg/day) vs. placebo. The Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS, Activated Protein C was withdrawn from the market) trial examined 1,241 patients with vasopressor- dependent septic shock randomized to 7d of hydrocorti- sone (50 mg iv q6h) and fludrocortisone (50 mcg enterally/ day) vs. placebo. APROCCHSS demonstrated improved 90-day mortality with hydrocortisone/fludrocortisone (43%) vs. placebo (49.1%, p=0.03) and had higher overall mor- tality than the ADRENAL trial which did not demonstrate a mortality benefit (hydrocortisone (27.9%) vs. placebo TUESDAY, MAY 21

RkJQdWJsaXNoZXIy MTM1ODMw